Profil
Barry M.
Sherman was the founder of Cassava Sciences, Inc. (1998) and StemPar Sciences, Inc. (2012), where he held the titles of Chief Medical Officer & Senior Vice President and President & Chief Executive Officer, respectively.
He also founded BiPar Sciences, Inc. Dr. Sherman's former jobs include President & Chief Executive Officer of Anergen, Inc., Chairman of Angiogenix, Inc., Director of SillaJen Biotherapeutics, Inc., Director of National Institutes of Health, Chief Medical Officer & Senior Vice President of Genentech, Inc., Professor-Medicine & Endocrinology at the University of Iowa, and Advisor at Quantum Technology Partners.
He served as an Independent Director at Rezolute, Inc. from 2015 to 2017.
Dr. Sherman received his undergraduate and doctorate degrees from the University of Michigan.
Anciens postes connus de Barry M. Sherman
| Sociétés | Poste | Fin |
|---|---|---|
| REZOLUTE, INC. | Directeur/Membre du Conseil | 30/11/2017 |
Angiogenix, Inc.
Angiogenix, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic solutions for chronic vascular diseases | Président | 06/03/2008 |
| FILANA THERAPEUTICS, INC. | Fondateur | 01/10/2001 |
National Institutes of Health
National Institutes of Health General GovernmentGovernment Engages in the improvement of health and saving lives | Directeur/Membre du Conseil | - |
University of Iowa
University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Formation de Barry M. Sherman
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 12 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Anergen, Inc.
Anergen, Inc. BiotechnologyHealth Technology Develops propriety therapeutics designed to interrupt the antigen process | Health Technology |
Cassava Sciences, Inc.
Cassava Sciences, Inc. BiotechnologyHealth Technology Manufactures and markets therapeutic products to detect and treat neurodegenerative diseases | Health Technology |
Angiogenix, Inc.
Angiogenix, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic solutions for chronic vascular diseases | Health Technology |
BiPar Sciences, Inc.
BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs for cancer patients | Health Technology |
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company provides clinical research and development services | Commercial Services |
University of Iowa
University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Michigan
University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Institutes of Health
National Institutes of Health General GovernmentGovernment Engages in the improvement of health and saving lives | Government |
Quantum Technology Partners
Quantum Technology Partners Investment ManagersFinance Quantum Technology Partners invests in companies located in the United States. The firm focuses on technology and life sciences. It participates in early stage transactions with an investment size ranging from USD 0.25 to 10 million. | Finance |
StemPar Sciences, Inc.
StemPar Sciences, Inc. Medical/Nursing ServicesHealth Services Develops cancer drugs treatments | Health Services |
Rezolute, Inc.
Rezolute, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for metabolic diseases related to chronic glucose imbalance | Health Technology |
















